Athersys (NASDAQ:ATHX) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

Other equities analysts have also issued research reports about the company. Maxim Group reaffirmed a “buy” rating and set a $6.00 price target on shares of Athersys in a research note on Tuesday, July 31st. Zacks Investment Research raised Athersys from a “sell” rating to a “hold” rating and set a $2.25 price target on the stock in a research note on Wednesday, August 8th.

Athersys stock opened at $2.18 on Wednesday. Athersys has a 52 week low of $1.29 and a 52 week high of $3.09.

Athersys (NASDAQ:ATHX) last posted its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported $0.05 EPS for the quarter. The company had revenue of $19.39 million for the quarter, compared to analyst estimates of $12.82 million. Athersys had a negative return on equity of 61.52% and a negative net margin of 106.99%. analysts anticipate that Athersys will post -0.21 EPS for the current year.

In other news, EVP John J. Harrington sold 15,000 shares of the company’s stock in a transaction on Friday, September 14th. The stock was sold at an average price of $1.91, for a total transaction of $28,650.00. Following the transaction, the executive vice president now owns 684,320 shares of the company’s stock, valued at $1,307,051.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Laura K. Campbell sold 14,420 shares of the company’s stock in a transaction on Thursday, August 2nd. The shares were sold at an average price of $2.01, for a total value of $28,984.20. Following the transaction, the insider now directly owns 602,944 shares in the company, valued at approximately $1,211,917.44. The disclosure for this sale can be found here. Insiders have sold 76,088 shares of company stock worth $149,487 in the last ninety days. 18.60% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of ATHX. BlackRock Inc. lifted its stake in shares of Athersys by 22.4% during the second quarter. BlackRock Inc. now owns 6,000,666 shares of the biopharmaceutical company’s stock valued at $11,821,000 after acquiring an additional 1,097,520 shares during the period. Millennium Management LLC lifted its stake in Athersys by 377.6% in the second quarter. Millennium Management LLC now owns 457,667 shares of the biopharmaceutical company’s stock valued at $902,000 after buying an additional 361,835 shares during the period. Alps Advisors Inc. acquired a new position in Athersys in the second quarter valued at about $394,000. Schwab Charles Investment Management Inc. lifted its stake in Athersys by 50.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 250,900 shares of the biopharmaceutical company’s stock valued at $495,000 after buying an additional 84,600 shares during the period. Finally, Northern Trust Corp lifted its stake in Athersys by 7.1% in the first quarter. Northern Trust Corp now owns 1,215,690 shares of the biopharmaceutical company’s stock valued at $2,225,000 after buying an additional 80,708 shares during the period. 19.02% of the stock is currently owned by institutional investors and hedge funds.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Recommended Story: What does earnings per share mean?

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.